Health resource utilisation associated with skeletal‑related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study

Lorusso,Vito; Duran,Ignacio; Garzon‑Rodriguez,Cristina; Lüftner,Diana; Bahl,Amit; Ashcroft,John; Hechmati,Guy; Wei,Rachel; Thomas,Emma; Hoefeler,Herbert

doi:10.3892/mco.2014.330

Health resource utilisation associated with skeletal‑related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study

Authors:
- Vito Lorusso
- Ignacio Duran
- Cristina Garzon‑Rodriguez
- Diana Lüftner
- Amit Bahl
- John Ashcroft
- Guy Hechmati
- Rachel Wei
- Emma Thomas
- Herbert Hoefeler
View Affiliations

Affiliations: Oncology Institute ASL, Lecce, Italy, Centro Integral Oncologica Clara Campal (CIOCC), Madrid, Spain, Catalan Institute of Oncology (ICO) ‑ Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, Berlin University of Medicine, Berlin, Germany, University Hospitals Bristol, Bristol, UK, Pinderfields General Hospital, Wakefield, UK, Health Economics, Amgen (Europe) GmbH, Zug, Switzerland, Department of Biostatistics, Amgen, Inc., Thousand Oaks, CA, USA, Scientific Publications, Amgen (Europe) GmbH, Zug, Switzerland, Research Center Ruhr, Witten, Germany
Published online on: June 27, 2014 https://doi.org/10.3892/mco.2014.330
Pages: 701-708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone complications or skeletal‑related events (SREs), typically defined as radiation to bone, pathological fractures, surgery to bone and spinal cord compression, occur frequently in patients with bone metastases. As the survival of patients with advanced lung cancer improves, preventing SREs is becoming increasingly clinically relevant. The aim of this analysis was to assess the impact of SREs on health resource utilisation (HRU) in European lung cancer patients with bone metastasis. This multinational, observational study included patients who had at least one SRE in the 97 days prior to enrolment, a life expectancy of ≥6 months and an Eastern Cooperative Oncology Group performance status of 0‑2. Data on HRU were retrospectively collected for up to 97 days prior to enrolment with a planned prospective follow‑up for up to 18‑21 months. The HRU measures included the number and length of inpatient hospitalisations and the number of outpatient visits and procedures. The investigators determined whether each HRU was attributable to a SRE. In total, 135 patients with lung cancer, enrolled at centres in Germany, Italy, Spain and the United Kingdom, contributed 214 SREs to this analysis. The median length [quartile (Q)1, Q3] of follow‑up ranged from 1.5 (0.7, 3.3) to 5.6 (2.0, 8.2) months across the countries. Overall, 41% of the SREs required an inpatient stay, with a median (Q1, Q3) duration of 19.0 (6.0, 28.0) days. Spinal cord compression and surgery to bone were the SRE types most frequently requiring inpatient stays. Radiation to bone was associated with the largest number of outpatient visits and procedures. All the SREs resulting from bone metastases in patients with lung cancer contribute considerably to HRU and efforts to minimise the incidence of bone complications in these patients through appropriate treatments may help reduce this burden.

View Figures

View References

1	Steliarova-Foucher E, O’Callaghan M, Ferlay J, et al: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0. September. 2012, European Network of Cancer Registries, International Agency for Research on Cancer. http://eco.iarc.fr. Accessed June 18, 2013
2	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
3	Galasko C: The anatomy and pathways of skeletal metastases. Bone Metastases. Weiss L and Gilbert A: GK Hall; Boston: pp. 49–63. 1981
4	Mok TS: Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol. 8:661–668. 2011. View Article : Google Scholar : PubMed/NCBI
5	Brodowicz T, O’Byrne K and Manegold C: Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rosen LS, Gordon D, Tchekmedyian NS, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 100:2613–2621. 2004. View Article : Google Scholar
7	Costa L, Badia X, Chow E, Lipton A and Wardley A: Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer. 16:879–889. 2008.
8	Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain. 69:1–18. 1997. View Article : Google Scholar : PubMed/NCBI
9	Loblaw DA, Wu JS, Kirkbride P, et al: Pain flare in patients with bone metastases after palliative radiotherapy - a nested randomized control trial. Support Care Cancer. 15:451–455. 2007. View Article : Google Scholar : PubMed/NCBI
10	Coleman RE: Skeletal complications of malignancy. Cancer. 80(Suppl 8): 1588–1594. 1997. View Article : Google Scholar
11	National Collaborating Centre for Cancer (UK). Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. Full guideline. May;2012.PubMed/NCBI
12	Loblaw DA, Perry J, Chambers A and Laperriere NJ: Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol. 23:2028–2037. 2005.
13	Katzer A, Meenen NM, Grabbe F and Rueger JM: Surgery of skeletal metastases. Arch Orthop Trauma Surg. 122:251–258. 2002. View Article : Google Scholar
14	Body JJ, Chevalier P, Gunther O, Hechmati G and Lamotte M: The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ. 16:539–546. 2013. View Article : Google Scholar : PubMed/NCBI
15	Delea T, Langer C, McKiernan J, et al: The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 67:390–396. 2004. View Article : Google Scholar : PubMed/NCBI
16	Delea T, McKiernan J, Brandman J, et al: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 4:341–347. 2006.PubMed/NCBI
17	Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL and Chung K: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 19:755–760. 2010. View Article : Google Scholar : PubMed/NCBI
18	Schulman KL and Kohles J: Economic burden of metastatic bone disease in the U.S. Cancer. 109:2334–2342. 2007. View Article : Google Scholar : PubMed/NCBI
19	Decroisette C, Monnet I, Berard H, et al: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 6:576–582. 2011. View Article : Google Scholar : PubMed/NCBI
20	Hoefeler H, Duran I, Hechmati G, et al: Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. J Bone Oncol. (In press).
21	Hechmati G, Cure S, Gouepo A, et al: Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 16:691–700. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lüftner D, Lorusso V, Duran I, et al: Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Submitted for publication. 2013.
23	Hoefeler H, Duran I, Hechmati G, et al: Health resource utilization (HRU) associated with skeletal-related events (SREs) by tumour type in patients with bone metastases/lesions: European analysis of a prospective multinational observational study. Eur J Cancer. 47:S262–S263. 2011.
24	Lüftner D, Lorusso V, Duran I, et al: Health resource utilization (HRU) associated with skeletal-related events (SREs) in advanced breast cancer patients with bone metastases: results from a prospective multinational observational study. Cancer Res. 71(24 Suppl): abstract P4-16-09. 2011.
25	Royal College of Radiologists. Single fraction radiotherapy for bone metastases. http://www.rcr.ac.uk/docs/oncology/pdf/bonemetsreport.pdf. Accessed June 27, 2013
26	Williams MV, Summers ET, Drinkwater K and Barrett A: Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol (R Coll Radiol). 19:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
27	Casas A, Lebret T, Cavo M, et al: Insights into the management of bone metastases: a comprehensive European survey. Support Care Cancer. 20:S882012.
28	Calderone R, Nimako K, Leary A, Popat S and O’Brien ME: Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease - a short communication. Eur J Cancer. 47:1603–1605. 2011. View Article : Google Scholar : PubMed/NCBI
29	Woll PJ, Flinois A, Schoen P, Shepherd S and Haynes I: Insights into the management of bone metastases in patients with lung cancer: A comprehensive European survey. Eur J Cancer. 49:abstract 3473. 2013.